Novartis Presentations at the 2021 ASH Annual Meeting
As part of scientific exchange, Novartis is providing the most recent abstract(s) accepted by the referenced medical congress. The scientific information may include data/information on investigational use(s) of compounds/drugs that efficacy and safety have not been established. Information available on this website is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of Novartis products.
ALL
Oral
Tisagenlecleucel (Abstract # 428)
Real-world Outcomes for Pediatric and Young Adult Patients With Relapsed or Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (ALL) Treated With Tisagenlecleucel: Update From the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry
Lead Author:
S. John
POSTER
Tisagenlecleucel (Abstract # 1768)
Optimizing Commercial Manufacturing of Tisagenlecleucel for Patients in the US: A 4-Year Experiential Journey
Lead Author:
M. Rodrigues
Poster
Tisagenlecleucel (Abstract # 3882)
Tisagenlecleucel Leukapheresis and Manufacturing Outcomes in Patients Less Than 3 Years of Age With Relapsed/Refractory Acute Lymphoblastic Leukemia
Lead Author:
J. Willert
Poster
Tisagenlecleucel (Abstract # 4105)
Pediatric Acute Lymphoblastic Leukemia: Database Analysis of Patients and Treatments in a National Public Healthcare System
Lead Author:
A. Seber
Oral
Asciminib (Abstract # 310)
Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib in Patients With Chronic Myeloid Leukemia in Chronic Phase After ≥2 Prior Tyrosine Kinase Inhibitors: Update After 48 Weeks
Lead Author:
M. Mauro
Poster
Asciminib (Abstract # 1478)
Trial in Progress: A Multicenter, Open Label, Randomized Phase III Study of Asciminib (80 mg Once Daily) vs Investigator-selected TKIs in Newly Diagnosed Adult Patients With Chronic Myeloid Leukemia in Chronic Phase
Lead Author:
J.E. Cortes
Poster
Asciminib (Abstract # 1485)
Treatment Patterns in Patients With Chronic Myeloid Leukemia in Chronic Phase in the Third Line of TKI Therapy and Beyond Based on Real-world Evidence
Lead Author:
T. Dahlén
Poster
Asciminib (Abstract # 1943)
Real-world Analysis of the Clinical and Economic Burden of Later Line in Chronic Myeloid Leukemia Patients in Italy
Lead Author:
M. Breccia
Poster
Asciminib (Abstract # 2561)
Trial in Progress: A Multicenter, Open-label, Phase Ib/II Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Philadelphia Chromosome–positive Chronic Myeloid Leukemia in Chronic Phase Treated With ≥1 Prior Tyrosine Kinase Inhibitor
Lead Author:
N. Hijiya
Poster
Asciminib (Abstract # 3599)
Trial in Progress: Asciminib in Monotherapy 4 CML (AIM4CML), a Phase IIIb Study of Asciminib Monotherapy in Patients With Chronic Myeloid Leukemia in Chronic Phase Without or With T315I Mutations
Lead Author:
D. Andorsky
Oral
Nilotinib (Abstract # 635)
Treatment-Free Remission (TFR) After Two Different Durations of Nilotinib Consolidation in Patients With Chronic Myeloid Leukemia (CML) Previously Treated With Imatinib: ENESTPath Study Results
Lead Author:
D. Rea
Poster
Nilotinib (Abstract # 1474)
First Interim Analysis of the Italian DANTE Study: De-escalation Before Treatment-Free Remission in Patients With Chronic Myeloid Leukemia Treated With First-line Nilotinib
Lead Author:
M. Breccia
Poster
MAK683 (Abstract # 1422)
Phase I/II Study of MAK683 in Patients With Advanced Malignancies, Including Diffuse Large B-Cell Lymphoma
Lead Author:
V. Ribrag
Oral
Tisagenlecleucel (Abstract # 92)
A Propensity Score Matched Comparison of Axi-Cel and Tisa-Cel for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Real-life: a LYSA Study From the DESCAR-T Registry
Lead Author:
E. Bachy
Oral
YTB323 (Abstract # 740)
A First-in-Human Study of YTB323, a Novel, Autologous CD19-Directed CAR-T Cell Therapy Manufactured Using the Novel T-Charge™ Platform, for the Treatment of Patients (Pts) With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Lead Author:
I. Flinn
Oral
Tisagenlecleucel (Abstract # 131)
Efficacy of Tisagenlecleucel in Adult Patients (Pts) With High-Risk Relapsed/Refractory Follicular Lymphoma (R/R FL): Subgroup Analysis of the Phase II ELARA Study
Lead Author:
C. Thieblemont
Poster
Tisagenlecleucel (Abstract # 1349)
A Retrospective Cohort Study of Treatment Outcomes of Adult Patients With Relapsed or Refractory Low-grade Follicular Lymphoma (ReCORD-FL)
Lead Author:
G. Salles
Poster
Tisagenlecleucel Abstract # 1360)
Treatment Regimens and Clinical Outcomes Among Follicular Lymphoma Patients Treated With Third-line Therapy in the United States: A Real-world EHR Study
Lead Author:
D. Dai
Poster
Tisagenlecleucel (Abstract # 2419)
Comparison of Clinical Outcomes Among Patients With Relapsed/Refractory Follicular Lymphoma Treated With Tisagenlecleucel in the ELARA Trial Versus a Real-world External Control Arm of Patients Treated With Standard of Care
Lead Author:
Y. Hao
Poster
Tisagenlecleucel (Abstract # 3528)
Efficacy Comparison of Tisagenlecleucel Versus Standard of Care in Patients With Relapsed or Refractory Follicular Lymphoma
Lead Author:
G. Salles
Poster
Tisagenlecleucel (Abstract # 3533)
Assessment of Healthcare Resource Utilization and Hospitalization Costs in Patients With Relapsed or Refractory Follicular Lymphoma Undergoing CAR-T Cell Therapy With Tisagenlecleucel: Results From the ELARA Study
Lead Author:
N. Fowler
Poster
Eltrombopag (Abstract # 3150)
Treatment of Immune Thrombocytopenia (ITP) With Eltrombopag – Results of the 4th Interim Analysis of the German Non-Interventional Trial RISA
Lead Author:
O. Meyer
Poster
Eltrombopag (Abstract # 3151)
A Phase II Study to Investigate the Efficacy and Safety of Eltrombopag in Combination With Dexamethasone as First-Line Treatment in Adult Patients With Newly Diagnosed Primary ITP (XPAG-ITP)
Lead Author:
M. Binder
Poster
Midostaurin (Abstract # 1303)
Midostaurin in Patients (Pts) With Newly Diagnosed FLT3-Mutation Negative Acute Myeloid Leukemia (AML): Final Results and Measurable Residual Disease (MRD) Analyses From the UNIFY Trial
Lead Author:
J. Cloos
Oral
Sabatolimab (Abstract # 244)
Efficacy and Safety of Sabatolimab (MBG453) in Combination With Hypomethylating Agents (HMAs) in Patients (Pts) With Very High/High-Risk Myelodysplastic Syndrome (vHR/HR-MDS) and Acute Myeloid Leukemia (AML): Final Analysis From a Phase Ib Study
Lead Author:
A.M. Brunner
Poster
Sabatolimab (Abstract # 2605)
Treatment Patterns and Overall Survival in Patients With Intermediate-Risk MDS: A Retrospective Analysis in the Spanish MDS Registry
Lead Author:
M. Diez-Campelo
Poster
Siremadlin (Abstract # 1283)
Preliminary Results From a Phase Ib Study Exploring MDM2 Inhibitor Siremadlin (HDM201) in Combination With B-Cell Lymphoma-2 (BCL-2) Inhibitor Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (HR-MDS)
Lead Author:
A.H. Wei
Poster
Siremadlin (Abstract # 3417)
Siremadlin (HDM201) is Well Tolerated and Demonstrates Clinical Activity in Patients With Acute Myeloid Leukemia Who Have Relapsed After Allogeneic Stem Cell Transplantation: A Subset Analysis of Safety and Preliminary Efficacy
Lead Author:
E.M. Stein
Oral
Ruxolitininb (Abstract # 169)
A Phase II Study of Ruxolitinib Pre-, During, and Post Hematopoietic Cell Transplantation for PAtients With Primary or Secondary Myleofibrosis
Lead Author:
G. Hobbs
Oral
Ruxolitinib (Abstract # 230)
Ruxulitinib Plus Nuvolimab in Patients With R/R Hodgkin Lymphoma After Failure of Post-Check Inhibitors: Preliminary Report on Safety and Efficacy
Lead Author:
V. Bachanova
Oral
Ruxolitinib (Abstract # 239)
A Real-World Evaluation of the Association Between Elevated Blood Counts and Thrombatic Events in Polycythemia Vera (Analysis of Data From the REVEAL Study)
Lead Author:
A.T. Gerds
Oral
Ruxolitininb (Abstract # 259)
Validation of Ampiregulin as a Monitoring Biomarker During treatment of Life-Threatening Acute GVHD: A Secondary Analysis of 2 Prospectove Clinical Trials.
Lead Author:
M. Pratta
Poster
Ruxolitinib (Abstract # 1489)
ADORE: A Randomized, Open-Label, Phase 1/2 Open-Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Patients With Myelofibrosis
Lead Author:
D.M. Ross
Poster
Ruxolitininb (Abstract # 1497)
Community Versus Academic Practice in Essential Thrombocythemia and Myelofibrosis: Differences in Clinical Characteristics, Diagnosis, Treatment Patterns, and Symptom Burden (Analysis of Data From the MOST Study)
Lead Author:
R. Lyons
Poster
Ruxolitininb (Abstract # 1502)
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Add-On Parsaclisib in Patients With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib
Lead Author:
A. Yacoub
Poster
Ruxolitininb (Abstract # 1505)
Does Early Intervention in Myelofibrosis Impact Outcomes? A Pooled Analysis of the COMFORT I and II Studies
Lead Author:
S. Verstovsek
Poster
Ruxolitininb (Abstract # 2333)
Novel Combination Therapy of Venetoclax and Ruxolitinib in the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia
Lead Author:
U. Borate
Poster
Ruxolitininb (Abstract # 2555)
Second Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors in Chronic Phase Chronic Myeloid Leukemia (CML)
Lead Author:
K. Sweet
Poster
Ruxolitininb (Abstract # 2579)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ruxolitinib Plus Parsaclisib in Patients With JAK- and PI3K-Inhibitor Treatment–Naive Myelofibrosis
Lead Author:
A. Yacoub
Poster
Ruxolitininb (Abstract # 2727)
Efficacy and Safety of Ruxolitinib and Steroids for Treating Patients With Relapsed or Refractory Multiple Myeloma
Lead Author:
J.R. Berenson
Poster
Ruxolitinib (Abstract # 3646)
Characteristics of High-Risk Polycythemia Vera Patients With Suboptimal Response to First-Line Therapy Who Switched to Ruxolitinib Vs Those Who Did Not Switch: Findings From PV-SWITCH, a Multinational, Retrospective Chart Review Study
Lead Author:
S. Koschmieder
Poster
Ruxolitininb (Abstract # 3647)
Subgroup Analysis From a Phase 2 Study of the Efficacy and Safety of Parsaclisib, a Selective PI3Kδ Inhibitor, in Combination With Ruxolitinib in Patients With Myelofibrosis (MF)
Lead Author:
A. Yacoub
Poster
Ruxolitinib (Abstract # 3909)
Patient-Reported Outcomes (PROs) Among Patients With Steroid-Refractory or -Dependent Chronic Graft-vs-Host Disease (cGVHD) Randomized to Ruxolitinib (RUX) vs Best Available Therapy (BAT)
Lead Author:
S.J. Lee
Poster
Ruxolitininb (Abstract # 4060)
Disability Associated With Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation
Lead Author:
B.K. Hamilton
Poster
LNP023 (Abstract # 2173)
12-Month Analysis of a Phase 2 Study of Iptacopan (LNP023) Monotherapy for Paroxysmal Nocturnal Hemoglobinuria
Lead Author:
J.H. Jang
Oral
Crizanlizumab (Abstract # 12)
Initial Safety and Efficacy Results From the Phase II, Multicenter, Open-Label SOLACE-Kids Trial of Crizanlizumab in Adolescents With Sickle Cell Disease (SCD)
Lead Author:
M.M. Heeney
Oral
Crizanlizumab (Abstract # 490)
Frequency of Vaso-Occlusive Crises Is Associated With Health-Related Quality of Life in Pediatric Patients With Sickle Cell Disease: US Cross-Sectional Surveys of Adolescents and Caregivers
Lead Author:
A.D. Campbell
Poster
Crizanlizumab (Abstract # 1950)
The Increased Burden of Sickle Cell Disease in Italy: Findings From the GREATalyS (Generating Real world Evidence Across ITALy in SCD) Study
Lead Author:
L. De Franceschi
Poster
Crizanlizumab (Abstract # 2032)
Characterization of Two Anti-P-Selectin Monoclonal Antibodies (mAbs): Crizanlizumab Shows Comparable or Stronger Effects Versus Inclacumab Across Cell Adhesion Assays In Vitro
Lead Author:
T. Rubic-Schneider
Poster
Crizanlizumab (Abstract # 2037)
Association of Hospitalization Due to Vaso-Occlusive Crisis With Subsequent Sickle Cell Disease-Related Organ Damage Hospitalization: Retrospective Analysis of 3-Year Observational Study Data
Lead Author:
M.M. Heeney
Poster
Crizanlizumab (Abstract # 2040)
Sickle Cell Disease in Sweden – Prevalence and Resource Use Estimated Through Population-Based National Registers
Lead Author:
C. Kjellander
Poster
Crizanlizumab (Abstract # 3025)
Sickle Cell Disease Mortality in Brazil: Real-World Evidence
Lead Author:
R.D. Cancado
Poster
Crizanlizumab (Abstract # 3026)
Experiences of Sickle Cell Disease (SCD) Reported by Healthcare Professionals (HCPs) Across Different Regions: International Sickle Cell World Assessment Survey (SWAY)
Lead Author:
I. Osunkwo
Poster
Crizanlizumab (Abstract # 3096)
A Phase II, Randomized, Multicenter, Open-Label Study Evaluating the Effect of Crizanlizumab and Standard of Care (SoC) Versus Standard of Care Alone on Renal Function in Patients With Chronic Kidney Disease Due to Sickle Cell Nephropathy (STEADFAST)
Lead Author:
S.F. Saraf
Poster
Crizanlizumab (Abstract # 3106)
Children in the United States With Sickle Cell Disease Experience Greater Educational Burden Than Those Living in Low/Middle Income and Other High-Income Countries
Lead Author:
F. El Rassi
Poster
Crizanlizumab (Abstract # 3107)
Association Between Hospitalised Vaso-Occlusive Crises and Acute/Chronic Complications in Sickle Cell Disease Patients Aged 16 Years and Older Using the French National Health Insurance Database (SNDS)
Lead Author:
J.B. Arlet
Poster
Crizanlizumab (Abstract # 3112)
Rare Cases of Infusion-Related Reactions (IRRs) Presenting As Pain Events During or After Crizanlizumab Infusion in Patients (Pts) With Sickle Cell Disease (SCD): A Systematic Evaluation of Post-Marketing (PM) Reports
Lead Author:
J. Kanter
Poster
Crizanlizumab (Abstract # 3113)
Early Evaluation of the Use of Crizanlizumab in Sickle Cell Disease: A National Alliance of Sickle Cell Centers Study
Lead Author:
J. Kanter
Poster
Crizanlizumab (Abstract # 4055)
Pediatric Hydroxyurea Treatment Patterns, Sickle Cell Disease-Related Complication Rates, and Costs in a Large US Administrative Claims Database: A Retrospective Analysis
Lead Author:
D. Manwani
Aggressive B-Cell Lymphoma
Aggressive B-Cell Lymphoma
Late-Breaking
Tisagenlecleucel (Abstract # LBA-6)
Tisagenlecleucel vs Standard of Care as Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III BELINDA Study
Lead Author:
M.R. Bishop
Oral
Tisagenlecleucel (Abstract # 429)
Real-world Efficacy and Safety Outcomes for Patients With Relapsed or Refractory (R/R) Aggressive B-Cell Non-Hodgkin’s Lymphoma (aBNHL) Treated With Commercial Tisagenlecleucel: Update From the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry
Lead Author:
D. Landsburg
Oral
Tisagenlecleucel (Abstract # 885)
Outcome of Relapsed/Refractory Aggressive B-Cell Lymphoma Patients Relapsing After Anti-CD19 CAR T-Cells and Enrolled in the DESCAR-T French National Registry
Lead Author:
R. Di Blasi
Aplastic Anemia
Aplastic Anemia
Poster
Eltrombopag (Abstract # 2174)
Efficacy and Safety of Eltrombopag Combined With Cyclosporine as First-Line Therapy in Adults With Severe Acquired Aplastic Anemia: Results of the Interventional Phase 2 Single-Arm SOAR Study
Lead Author:
C. Vallejo
Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Poster
Ianalumab (Abstract # 2631)
Investigating the Addition of Ianalumab (VAY736) to Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL) on Ibrutinib Therapy: Results From a Phase Ib Study
Lead Author:
K.A. Rogers
Poster
RWE (Abstract # 1559)
Real-World Evaluation of the Treatment Landscape for Chronic Lymphocytic Leukemia
Lead Author:
T.W. Smith
Langerhans Cell Histicytosis
Langerhans Cell Histicytosis
Poster
Dabrafenib (Abstract # 3618)
Dabrafenib, Alone or in Combination With Trametinib, in Pediatric Patients With BRAF V600 Mutation-Positive Langerhans Cell Histiocytosis
Lead Author:
J.A. Whitlock
Multiple Myeloma
Multiple Myeloma
Poster
PHE885 (Abstract # 2770)
Identification and Development of PHE885: A Novel and Highly Potent Fully Human Anti-BCMA CAR-T Manufactured With a Novel T-ChargeTM Platform for the Treatment of Multiple Myeloma
Lead Author:
D. Bu
Poster
PHE885 (Abstract #3864)
Phase I Study of PHE885, a Fully Human BCMA-Directed CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma Manufactured in <2 days using the t-chargetm platform>
Lead Author:
A. Sperling
Other
Other
Oral
YTB323 (Abstract # 2848)
Preservation of T-Cell Stemness With a Novel Expansionless CAR-T Manufacturing Process, Which Reduces Manufacturing Time to Less Than Two Days, Drives Enhanced CAR-T Cell Efficacy
Lead Author:
B. Engels
